News

The vaccine candidate is ASP0113, which was in development to treat and prevent cytomegalovirus (CMV) in hematopoietic stem cell transplant recipients.

The Cystic Fibrosis Foundation has awarded Motif Bio with $120,000 that will fund in vitro testing for the development of iclaprim to benefit patients with cystic fibrosis who have lung infections.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

At one of the worst times, as hospitals are already over capacity with more influenza patients than ever before, the United States is battling an IV bag shortage.

In case you missed them, we've compiled a list of the latest US Food and Drug Administration (FDA) recalls posted this week.

The FDA has approved Allergan's sNDA to expand the approved use of AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

The World Health Organization (WHO) released its first report on antibiotic resistance surveillance data.

Findings from a new National Institutes of Health study may have important implications for flu vaccine development.

The FDA grants 510(k) clearance to TECHLAB to market 2 noninvasive tests intended to aid in the diagnosis of campylobacteriosis.

An ongoing study aims to confirm that newer ART regimens are as safe for pregnant women living with HIV as they are for their non-pregnant counterparts.

E. Canadensis tapeworms may be under-recognized in the United States.

Emerging and neglected tropical diseases are on the rise in Texas, and now, a new paper explores what state health officials need to do in response.

Historically, postoperative pulmonary complications have been the most common serious adverse event following upper abdominal surgery, with incidence rates ranging from 10% to 50%.

Amid alleged tobacco investments, Brenda Fitzgerald has resigned from her position as director of the CDC.

A multinational team of investigators has revealed a link between conflict-induced displacement of people and the spread of HIV within Ukraine.

With about 1 million individuals getting herpes zoster each year in the United States, the best protection against the virus is vaccination.

As this season’s flu continues to drive patients to hospitals in droves, an IV bag shortage and tapped out staffing makes infection control particularly difficult.

The FDA grants Fast Track designation to TAK-426, Takeda’s purified, inactivated, alum-adjuvanted whole Zika virus vaccine candidate.

As flu cases continue to rapidly increase this season, school districts around the country have taken to closing schools in order to prevent the spread of the virus.

In a NIDCR symposium, a panel of speakers discussed autotherapies and how they can enhance the body’s innate healing ability.

The fluoroquinolone exhibits activity against both gram-positive and gram-negative pathogens, including methicillin-resistant Staphylococcus aureus, and is available in both intravenous and oral formulations.

The FDA has approved Firvanq for the treatment of C. diff-associated diarrhea and enterocolitis caused by Staphylococcus aureus.

Whole genome sequencing proved useful in identifying patients with multidrug-resistant tuberculosis in an outbreak among African refugees in Europe.

Vela Diagnostics has reached an agreement with the University of California, San Francisco for licensing 2 technologies.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

In case you missed them, we've compiled a list of the latest US Food and Drug Administration (FDA) recalls posted this week.

The CDC announces an investigation of a multistate Salmonella outbreak linked with raw sprouts served at Jimmy John’s.

Aetna has agreed to a $17 million settlement of a lawsuit centering around the HIV privacy violation that affected approximately 12,000 of the insurer’s customers in 2017.

More than $2 billion was invested in research and development relevant to the issue of antimicrobial resistance in 2016 alone.

The FDA grants PMA approval for the Aptima HBV Quant Assay for the quantitation of hepatitis B viral load on the Panther system.